Child Neurology: Hemiconvulsion-Hemiplegia-Epilepsy Syndrome in the Setting of COVID-19 Infection and Multisystem Inflammatory Syndrome

Paul Gong, MD, Cemal Karakas, MD, and Bethanie Morgan, MD

Neurology® 2022;99:756-760. doi:10.1212/WNL.000000000000201226

Abstract

Hemiconvulsion-hemiplegia-epilepsy (HHE) syndrome is a rare pediatric epilepsy syndrome characterized by prolonged focal febrile convulsive status epilepticus with unilateral hemispheric cerebral edema, followed by the subsequent development of hemiplegia, global atrophy of the affected hemisphere, and epilepsy. The pathophysiology of HHE syndrome remains poorly understood though is clearly multifactorial. Factors thus far implicated are hyperthermia, proinflammatory state, and cytotoxic edema from prolonged ictal activity. Prognosis is variable, from the resolution of hemiplegia and seizures to permanent hemiparesis and refractory epilepsy. We describe a 2-year-old boy who presented with superrefractory focal status epilepticus in the setting of acute coronavirus infectious disease-2019 (COVID-19) and multisystem inflammatory syndrome in children (MIS-C). He had right-sided hemiplegia on neurologic examination, and an MRI examination of the brain showed left cerebral hemispheric edema consistent with HHE syndrome. Our case represents the first report in the literature on HHE syndrome in the setting of acute COVID-19 and MIS-C.

Case Report

Clinical History

A 2-year-old boy was admitted to our hospital with convulsive status epilepticus (SE). His medical history included a previous complex febrile seizure (CFS), consisting of a febrile right focal motor seizure. Then, the EEG showed delta slowing in the left hemisphere with predominance in the posterior left temporal-parietal region intermixed with sharp waves. An MRI examination of the brain without contrast was normal. He was not started on antiseizure medications (ASMs) and was prescribed rectal diazepam as needed. He was otherwise healthy and met all developmental milestones. A family history was significant for seizures associated with an unspecified brain lesion in the mother. There were no further concerns for seizures until his presentation to our hospital 4 months after his CFS.

On admission to our hospital, his parents reported a right-sided predominant generalized tonic-clonic seizure at home. The time of seizure onset was unclear. His parents found him having a seizure after laying him down for a nap. They administered 7.5 mg of diazepam rectally, but his seizure persisted. He was taken to an outside facility and required intubation for airway protection due to ongoing SE. Multiple doses of 0.1 mg/kg of IV midazolam were necessary to abort the seizure. The duration of SE from the time noted by parents to cessation at the local hospital was approximately 1 hour. On neurologic examination, he had a left gaze preference, right facial weakness, and right-sided hemiplegia. He was subsequently transferred to the pediatric intensive care unit (PICU) in our hospital.
In the PICU, he had clinical and electrographic only seizures refractory to treatment. He received multiple ASM loading doses and required placement on continuous midazolam infusion for 10 days due to persistent seizures over multiple days. He also had a recurrence of SE when attempting to wean the infusion initially. He was treated with high-dose IV methylprednisolone due to findings of worsening cerebral edema and midline shift on repeat MRI of the brain. Seizure frequency decreased after treatment with methylprednisolone, but because the patient was also receiving multiple ASMs concurrently, the effect of methylprednisolone, if any, could not be determined. After weaning off continuous midazolam infusion, he was continued on multiple ASMs (Figure 1). The EEG initially showed focal seizures of the left hemisphere consisting of high-amplitude spike/polyspike and wave discharges. He then had seizures localized to the left posterior quadrant and right posterior quadrant. A sample of the EEG is provided in eFigure 1 (links.lww.com/WNL/C271). After resolution of seizures, the EEG showed decreased background amplitude and frequency of the left hemisphere when compared with that of the right, consisting of polymorphic 0.5–2 Hz delta activity.

**Laboratory Results**

He was febrile to 103°F, so was tested for coronavirus infectious disease-2019 (COVID-19). PCR testing showed positive results. Inflammatory markers, including procalcitonin, beta natriuretic peptide, lactate dehydrogenase, ferritin, D-dimer, and C-reactive protein levels, were elevated. He had elevated transaminases, which gradually normalized, and elevated blood urea nitrogen, concerning for acute kidney injury, which improved over time. Given multiorgan dysfunction with elevated inflammatory markers, his presentation was consistent with multisystem inflammatory syndrome in children (MIS-C). He was treated for MIS-C with IV methylprednisolone, IV immunoglobulin, and anakinra (Figure 1).

Testing for other intercurrent infections showed negative results for pathogens on blood, urine, and CSF cultures. CSF pathogen panel also showed negative results. Additional information about the panel is listed in eTable 1 (links.lww.com/WNL/C271). CSF studies showed no pleocytosis and normal glucose and protein levels. CSF COVID-19 PCR was not tested. An epilepsy gene panel was inconclusive, revealing 3 heterozygous variants of uncertain significance in CNTN2 (c.1315C>G [p.Pro439Ala], associated with autosomal recessive disease [ARD]), EHMT1 (c.818A>G [p.Gln273Arg], associated with ARD), and RELN (c.10131C>G [p.His3377Gln], associated with ARD) genes. Additional information is listed in eTable 2 in the Supplement.

**Table 1** Timeline for Medications Administered During Hospitalization

<table>
<thead>
<tr>
<th>Medications</th>
<th>Hospital day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levetiracetam 60 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td>Phenobarbital 10 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td>Lacoxamide 9 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td>Clobazam 0.7 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td>Continuous midazolam infusion</td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone 30 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td>IVIG 1 g/kg/day</td>
<td></td>
</tr>
<tr>
<td>Anakinra 2 mg/kg/day</td>
<td></td>
</tr>
</tbody>
</table>

**Neuroimaging Results**

3T MRIs of the brain without contrast on hospital day 2, day 5, and day 12 revealed edema in the left cerebral hemisphere, left basal ganglia, left thalamus, left amygdala/hippocampus, and the left subcortical white matter with
associated restricted diffusion (Figure 2). Magnetic resonance angiography (MRA) of the brain was normal.

**Follow-up**

On a follow-up examination on hospital day 5, gaze preference and facial droop had resolved. The patient had gradual improvement in right-sided motor strength throughout the admission. After transferring out of the PICU on hospital day 17, the patient did not have any further breakthrough seizures. He continued to have improved but persistent right-sided hemiparesis and right-sided spasticity on discharge to acute inpatient rehabilitation on hospital day 32. No further neuroimaging was performed after discharge from the hospital.

At the 6-month outpatient follow-up visit, the patient had only 1 focal seizure with altered awareness since discharge. He was maintained on levetiracetam, phenobarbital, and clobazam. He was placed on baclofen for right-sided spasticity and referred for outpatient physical and occupational therapies.

**Discussion**

Our patient had superrefractory focal febrile SE in the setting of acute, symptomatic COVID-19 and MIS-C. His overall presentation was consistent with hemiconvulsion-hemiplegia-epilepsy (HHE) syndrome.

Although first described by Gastaut and colleagues more than 6 decades ago, the pathophysiology of HHE syndrome remains unclear. Fever and prolonged focal convulsive seizures in children younger than 4 years are typical of the clinical presentation. Children subsequently develop hemiplegia, global atrophy of the affected hemisphere, and epilepsy. Of patients who develop epilepsy, 85% do so within the first 3 years after presentation. Unilateral edematous hemispheric swelling, independent of any vascular territory, is seen during initial SE, and prominent diffusion restriction of the basal ganglia, internal capsule, and thalamus is also seen. Etiology is divided into idiopathic or those associated with an identified predisposing factor. There are case reports of HHE syndrome associated with...
pathogenic genetic variants, for example, CACNA1A and SCN1A, and with structural brain abnormalities, such as focal cortical dysplasia. Our patient had negative genetic testing. His initial MRI of the brain at 2 years of age was normal though, given it was performed without contrast and was not an epilepsy protocol study, underlying focal structural abnormalities cannot be ruled out.

Hyperthermia is a salient feature of HHE clinical presentation, and it has been hypothesized that HHE syndrome represents a severe form of CFS. Febrile seizures are defined as seizures occurring in childhood (typically from 6 months to 5 years of age) associated with a febrile illness and no other acute CNS infection or acute metabolic derangements. CFSs are seizures having a focal onset, occurring more than once during the same febrile illness or lasting longer than 10–15 minutes.

Certain neurotropic viruses, such as human herpesvirus (HHV)-6 and HHV-7, have been postulated as causative agents in CFS and SE. Both were negative in our patient. It is unclear at this time whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has neurotropic properties akin to HHV-6 or HHV-7.

There have been case reports of HHE syndrome associated with coagulation disorders such as protein S deficiency and factor V Leiden mutation. Given the known association of COVID-19 with a hypercoagulable state and development of thrombotic complications, it is possible acute coagulopathy also contributed to the development of HHE syndrome in our patient, although MRA of the brain was normal.

The literature regarding the diverse neurologic complications of acute and postacute COVID-19 infection continues to grow. Several neurologic complications of COVID-19, such as Guillain-Barré syndrome, arterial ischemic stroke, cranial neuropathies, meningoencephalitis, and epilepsy, have been reported. Acute encephalitis with focal neurologic signs, seizures, and EEG abnormalities also has been described in association with MIS-C. A recent case report described a pediatric patient with MIS-C who presented with febrile SE and whose clinical picture was suggestive of febrile infection–related SE.

Given the high prevalence of COVID-19 and the poor understanding of the pathophysiology of HHE syndrome, our case ultimately describes an association of HHE syndrome with COVID-19. Thus, a limitation of the study is that it cannot prove the causative role of COVID-19 in the development of HHE syndrome. It is unclear whether the virus SARS-CoV-2 itself or the secondary immune dysregulation of MIS-C had any causative effect on the development of HHE syndrome in our patient. The HHE syndrome may represent a severe form of CFS, and because our patient had a previous CFS and previous focal abnormalities on EEG, it is possible he had a predisposing epileptic focus on the affected side despite previous negative MRI of the brain. This may explain the laterality of the seizures in the setting of high fevers triggered by acute COVID-19 and MIS-C and the subsequent unilateral edema of the epileptic hemisphere.

**Conclusion**

Our patient represents the first report of HHE syndrome associated with COVID-19 and MIS-C. As the literature has shown an association of HHE syndrome with acute febrile illnesses, infections with SARS-CoV-2 may also contribute as an etiologic trigger for the syndrome. Given the growing literature on neurologic conditions associated with COVID-19, our case adds to the list of possible associations and should prompt clinicians to consider COVID-19 and MIS-C when investigating future cases of HHE syndrome. More research is necessary to improve our understanding of the syndrome, improve recognition of the entity, develop effective treatment strategies for those patients affected, and optimize neurologic outcomes.

**Study Funding**

No targeted funding reported.

**Disclosure**

The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

**Publication History**

Received by Neurology January 26, 2022. Accepted in final form July 27, 2022. Submitted and externally peer reviewed. The handling editor was Whitley Aamodt, MD, MPH.
References


Subspecialty Alerts by E-mail!

Customize your online journal experience by signing up for e-mail alerts related to your subspecialty or area of interest. Access this free service by clicking on the “My Alerts” link on the home page. An extensive list of subspecialties, methods, and study design choices will be available for you to choose from—allowing you priority alerts to cutting-edge research in your field!

Neurology® Online CME Program

Earn CME while reading Neurology. This program is available to AAN members and to online Neurology subscribers. Read the articles marked CME, go to Neurology.org, and click on the CME link. The American Academy of Neurology (AAN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. Neurology is planned and produced in accordance with the ACCME Essentials. For more information, contact AAN Member Services at 800-879-1960.

Call for Voices: Lived Experiences

The Editor of the Neurology specialty section Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDES) encourages you to submit short first-person accounts (1,000 words or less) of experiences lived within the realm of IDEAS with the goal of informing and enlightening our community on these critical issues. Some topics to consider include, but are not limited to:

• Descriptions of personal experiences that shaped your views of IDEAS.
• Reflections on the intersection between personal identity and career.
• Discussions at the intersection of IDEAS and neurology patient care, research, education, advocacy, or policy.

Submit your contributions to journal@neurology.org and include “Voices Submission” in the subject line.
Child Neurology: Hemiconvulsion-Hemiplegia-Epilepsy Syndrome in the Setting of COVID-19 Infection and Multisystem Inflammatory Syndrome
Paul Gong, Cemal Karakas and Bethanie Morgan
Neurology 2022;99;756-760 Published Online before print August 25, 2022
DOI 10.1212/WNL.0000000000201226

This information is current as of August 25, 2022